Novo Nordisk

Novo Nordisk A/S is a world-leading biopharmaceutical company, holding a top position globally in the development and production of insulin for diabetes treatment. It pioneered the launch of long-acting insulin, pre-mixed insulin, highly purified insulin, human insulin, and insulin injection pens. Additionally, Novo Nordisk A/S was the first to introduce a new class of oral hypoglycemic drugs, significantly enhancing the level of diabetes treatment and control, and improving the quality of life for people with diabetes. Moreover, Novo Nordisk A/S maintains a leading position worldwide in many areas such as coagulation therapy, growth care, and hormone replacement therapy.